ClichemBIO develops a clickable albumin nanoplatform for targeted diagnostics and nanotherapeutics, specifically addressing the challenges of drug delivery and efficacy in treating inflammatory and cancerous diseases. This technology enhances drug circulation and targeting precision, significantly improving treatment outcomes while minimizing toxicity.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug delivery methods for treating inflammatory and cancerous diseases often lack precision, leading to systemic toxicity and reduced therapeutic efficacy. Effective targeting of diseased tissues and controlled drug release remain significant challenges in nanomedicine.
Solution
ClichemBIO develops a clickable albumin nanoplatform (CAN) technology for targeted drug delivery and diagnostics, enhancing treatment outcomes for inflammatory and cancerous diseases. The platform leverages click chemistry to functionalize albumin nanoparticles, enabling precise control over drug loading, targeting, and release kinetics. Glycation of the albumin surface allows for tailored interactions with specific cell types, such as macrophages, while minimizing off-target effects. The company's lead drug complex, ALBOMB, utilizes a structure-based approach to load drugs into albumin pockets, improving drug stability and reducing toxicity. This nanotheranostic approach aims to improve drug circulation, enhance targeting precision, and ultimately improve treatment efficacy.
Target Audience
ClichemBIO's primary target audience includes pharmaceutical companies seeking advanced drug delivery technologies, as well as researchers and clinicians focused on developing targeted therapies for inflammatory and cancerous diseases.
Features
- Clickable Albumin Nanoplatform (CAN) for controlled drug and biomolecule delivery
- Surface glycation for fine-tuned targeting of specific cell types
- ALBOMB drug complex utilizing albumin pockets for enhanced drug loading and reduced toxicity
- Tunable drug release kinetics for sustained therapeutic effect
- Capability to target SPARC and GLUT expressing cancers
- Potential for Boron Neutron Capture Therapy (BNCT) using Fol-CAN-10B
- Development of theranostic agents with imaging capabilities using GUL-CAN/ICG and Fol-CAN/ICG